His talk, entitled “Insights into hepatic stellate cell regulation and emerging antifibrotic treatments“ will take place at 10am in the Conference Room on the ground floor of the building at 184 rue du Faubourg Saint-Antoine, Paris.
Hepatic stellate cell activation remains a compelling and complex focus of efforts to develop antifibrotic therapies. I will review how we integrate data from animal models and evolving bioinformatics methods to define the contribution of this cell type to hepatic fibrosis and repair, and how we prioritize both emerging targets of antifibrotic therapies, and address the challenges of testing these agents in clinical trials.
Prof. Scott Friedman is the Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine, Mount Sinai. He has performed pioneering research into the underlying causes of scarring, or fibrosis associated with chronic liver disease, affecting millions worldwide. Dr. Friedman was the first to isolate and characterize the hepatic stellate cell, the key cell type responsible for scar production in liver. He has won many awards in the field of liver disease and its treatment, and is also the current President of the American Association for the Study of Liver Diseases.